Vaccine safety surveillance in South Africa through COVID-19 : a journey to systems strengthening

dc.contributor.authorSankar, Chenoa
dc.contributor.authorMeyer, Johanna C.
dc.contributor.authorSchonfeldt, Marione
dc.contributor.authorGunter, Hannah
dc.contributor.authorDawood, Halima
dc.contributor.authorSekiti, Victoria
dc.contributor.authorPickard, Naseera
dc.contributor.authorMubaiwa, Lawrence
dc.contributor.authorMawela, Dini
dc.contributor.authorDlamini, Sipho
dc.contributor.authorPeter, Jonny
dc.contributor.authorSpencer, David
dc.contributor.authorGray, Clive
dc.contributor.authorPatel, Vinod
dc.contributor.authorBamford, Lesley
dc.contributor.authorSehloho, Tohlang
dc.contributor.authorMcCarthy, Kerrigan
dc.date.accessioned2025-02-06T11:53:05Z
dc.date.available2025-02-06T11:53:05Z
dc.date.issued2025-02
dc.descriptionDATA AVAILABILITY : The authors do not have permission to share data.en_US
dc.description.abstractBACKGROUND : Surveillance systems for monitoring and reporting adverse events following immunisation (AEFI) and adverse events of special interest (AESI) are vital in understanding safety profiles of post-marketed vaccines. Evaluation of surveillance systems is necessary for systems strengthening. We conducted the first evaluation of the South African AEFI surveillance system in its current form, established in 2018. METHODS : Using CDC guidelines for evaluation of surveillance systems, we conducted a cross-sectional evaluation of system attributes, including quantitative analyses of AEFI/AESI data from 17 May 2021 to 31 December 2022 and qualitative analyses through semi-structured interviews with AEFI surveillance personnel. Findings were used to generate recommendations for system strengthening. RESULTS : The system collects and manages AEFI data, employs investigative tools and has an established AEFI review committee conducting causality assessment, thus meeting WHO minimal capacity for vaccine safety. System adaptation through inclusion of digital applications facilitated public reporting, whilst increasing complexity of database management. Respondents demonstrated engagement with the system through accounts of their roles in AEFI surveillance. Between 17 May 2021 and 31 December 2022, 37,537,009 COVID-19 vaccine doses (BNT162b2 and Ad26.COV2·S) were administered, and 3846 AEFI reported in relation to these vaccines (reporting rate: 10.2/100,000 doses). AEFI reporting rates varied considerably across provinces, ranging from 1.6 to 59.5 AEFI/100,000 doses. In this time period 283 AEFI were reported in relation to non-COVID-19 vaccines. By 31 December 2022, 73.5 % of severe cases that were investigated were causality assessed. CONCLUSION : We observed a functional, useful, flexible system with high reported stakeholder and public acceptability levels. System challenges included low reporting rates from particular provinces, weak co-ordination between paper and digital reporting and human resource constraints. Recommendations include integration of paper-based and digital surveillance reporting systems to enhance signal detection and eliminate data duplication, provision of dedicated human and financial resources at provincial level and inclusion of active AEFI surveillance through cohort event monitoring.en_US
dc.description.departmentPaediatrics and Child Healthen_US
dc.description.librarianhj2024en_US
dc.description.sdgSDG-03:Good heatlh and well-beingen_US
dc.description.urihttps://www.elsevier.com/locate/vaccineen_US
dc.identifier.citationSankar, C., Meyer, J.C., Schönfeldt, M. et al. 2025, 'Vaccine safety surveillance in South Africa through COVID-19: a journey to systems strengthening', Vaccine, vol. 46, art. 126535, pp. 1-11, doi : 10.1016/j.vaccine.2024.126535.en_US
dc.identifier.issn0264-410X (print)
dc.identifier.issn1873-2518 (online)
dc.identifier.other10.1016/j.vaccine.2024.126535
dc.identifier.urihttp://hdl.handle.net/2263/100584
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.rights© 2024 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by- nc-nd/4.0/).en_US
dc.subjectPublic healthen_US
dc.subjectSurveillanceen_US
dc.subjectAdverse events following immunisation (AEFI)en_US
dc.subjectPharmacovigilanceen_US
dc.subjectVaccine safetyen_US
dc.subjectAdverse events of special interest (AESI)en_US
dc.subjectSDG-03: Good health and well-beingen_US
dc.titleVaccine safety surveillance in South Africa through COVID-19 : a journey to systems strengtheningen_US
dc.typeArticleen_US

Files

Original bundle

Now showing 1 - 2 of 2
Loading...
Thumbnail Image
Name:
Sankar_Vaccine_2025.pdf
Size:
1.5 MB
Format:
Adobe Portable Document Format
Description:
Article
Loading...
Thumbnail Image
Name:
Sankar_VaccineSuppl_2025.docx
Size:
16.87 KB
Format:
Microsoft Word XML
Description:
Supplementary Material

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: